Recent Updates
Recently added Catalysts

mRNA-1325

Phase 1

Zika Virus | Monoclonal antibody | Infectious Disease |Moderna, Inc.|Last Updated: Aug 21, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment90
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03014089Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult SubjectsPHASE1 COMPLETED 90Dec 21, 2016Jul 31, 2019Aug 21, 20243 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Part A: Number of Participants With Solicited Adverse Events- Vaccination 1
Up to 7 days post-vaccination 1 (up to 8 days)

Solicited adverse reactions (ARs) (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema, and injection site induration/swelling. Systemic ARs included: body temperature (oral), generalized myalgia (muscle ache or pain), generalized arthralgia (joint ache or pain), headache, fatigue/malaise (unusual tiredness), nausea/vomiting, chills, and rash. Data for this outcome measure is reported up to 7 days after the first study vaccination only. A summary of all serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.

Part A: Number of Participants With Solicited Adverse Events: Vaccination 2
Up to 7 days post-vaccination 2 (Day 29 to Day 36)

Solicited adverse reactions (ARs) (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema, and injection site induration/swelling. Systemic ARs included: body temperature (oral), generalized myalgia (muscle ache or pain), generalized arthralgia (joint ache or pain), headache, fatigue/malaise (unusual tiredness), nausea/vomiting, chills, and rash. Data for this outcome measure is reported up to 7 days after the second study vaccination only. A summary of all serious AEs (SAEs) and all nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.

Part A: Number of Participants With Unsolicited Adverse Events
Up to Day 392 (all AEs considered an SAE were collected till end of study [Day 392]; the Other AEs [non-SAE] were collected up to Day 57)

An unsolicited AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The treatment-emergent AEs are defined as any event not present before exposure to study drug or any event already present that worsened in intensity or frequency after exposure. A summary of all SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section.

Part A: Number of Participants With Medically-Attended Adverse Events (MAAEs)
Up to 1 year post-vaccination (Day 392)

An MAAE is an AE that leads to an unscheduled visit to an healthcare practitioner. A summary of all SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
Up to 1 year post-vaccination (Day 392)

An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions was a congenital anomaly/birth defect, or was an important medical event. AESIs included potentially immune-mediated medical conditions (autoimmune or autoinflammatory diseases) that may have the theoretical potential for association with novel vaccines. A summary of all SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Secondary Endpoints
Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus
Baseline, 28 days post each vaccination (Days 29 and 57)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
mRNA-1325EXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR0.9% sodium chloride
Interventions
NameTypeDescription
mRNA-1325BIOLOGICALEscalating dose levels
PlaceboOTHER -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 49 Years
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion * 18 to 49 years of age * Body mass index between 18 and 35 kg/m2 * In good health as determined by medical history * Female subjects must be non pregnant and non lactating and meet one of the following criteria: a) post menopausal b) surgically sterile * Women of childbearing potential m...

Countries:United States
Unlock Eligibility Criteria